|
| Geron's Clinical Trial: Risk, Front-loading and Costs
July 31, 2010 at 9:47 PM
|
| | The Vatican doesn't particularly care for the idea. "Unacceptable" was the word it used. Over at Bioworld Today, it was "the dawn of a new era." A reader of the New York Times warned of the danger of "front-loaded" arguments that can be detrimental to stem cell research. What they were talking about is Geron and its re-vitalized clinical trial of an hESC therapy for spinal injuries. The FDA | | | | 
| This email was sent to agupta1213+termsc@gmail.com. Account Login
Don't want to receive this feed any longer? Unsubscribe here
This email was carefully delivered by Feed My Inbox. 230 Franklin Road Suite 814 Franklin, TN 37064 | |
No comments:
Post a Comment